These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19543143)

  • 1. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom.
    Woodhall SC; Jit M; Cai C; Ramsey T; Zia S; Crouch S; Birks Y; Newton R; Edmunds WJ; Lacey CJ
    Sex Transm Dis; 2009 Aug; 36(8):515-21. PubMed ID: 19543143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
    Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
    Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
    BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining the cost of genital warts: a study from Ireland.
    Dee A; Howell F; O'Connor C; Cremin S; Hunter K
    Sex Transm Infect; 2009 Sep; 85(5):402-3. PubMed ID: 19004863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-based programs for vaccination against HPV.
    Elbasha EH; Dasbach EJ; Insinga RP; Haupt RM; Barr E
    Value Health; 2009; 12(5):697-707. PubMed ID: 19490561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genital warts and HPV vaccination].
    Pilka R; Dvorák V; Fait T
    Ceska Gynekol; 2011 Dec; 76(6):468-70. PubMed ID: 22312844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
    Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
    PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.
    Jit M; Chapman R; Hughes O; Choi YH
    BMJ; 2011 Sep; 343():d5775. PubMed ID: 21951758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Male and Female Genital Warts Among Adolescents in a Safety-Net Health Care System 2004-2013: Correlation With Introduction of Female and Male Human Papillomavirus Vaccination.
    Perkins RB; Legler A; Hanchate A
    Sex Transm Dis; 2015 Dec; 42(12):665-8. PubMed ID: 26562694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.
    Donovan B; Franklin N; Guy R; Grulich AE; Regan DG; Ali H; Wand H; Fairley CK
    Lancet Infect Dis; 2011 Jan; 11(1):39-44. PubMed ID: 21067976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A brief history of economic evaluation for human papillomavirus vaccination policy.
    Beutels P; Jit M
    Sex Health; 2010 Sep; 7(3):352-8. PubMed ID: 20719227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data.
    Ali H; Donovan B; Wand H; Read TR; Regan DG; Grulich AE; Fairley CK; Guy RJ
    BMJ; 2013 Apr; 346():f2032. PubMed ID: 23599298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns and associated costs for genital warts in Italy.
    Merito M; Largeron N; Cohet C; Timelli L; Boselli F; Matteelli A; Naldi L; Vittori G
    Curr Med Res Opin; 2008 Nov; 24(11):3175-83. PubMed ID: 18851777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing incidence and economic burden of genital warts with data from a US commercially insured population.
    Hoy T; Singhal PK; Willey VJ; Insinga RP
    Curr Med Res Opin; 2009 Oct; 25(10):2343-51. PubMed ID: 19650749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme.
    Chow EP; Read TR; Wigan R; Donovan B; Chen MY; Bradshaw CS; Fairley CK
    Sex Transm Infect; 2015 May; 91(3):214-9. PubMed ID: 25305210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence of genital warts in Australian women prior to the national vaccination program.
    Brotherton JM; Heywood A; Heley S
    Sex Health; 2009 Sep; 6(3):178-84. PubMed ID: 19653953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France].
    Monsonégo J; Breugelmans JG; Bouée S; Lafuma A; Bénard S; Rémy V
    Gynecol Obstet Fertil; 2007 Feb; 35(2):107-13. PubMed ID: 17270482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
    Sharma M; Sy S; Kim JJ
    BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK.
    Woodhall SC; Jit M; Soldan K; Kinghorn G; Gilson R; Nathan M; Ross JD; Lacey CJ;
    Sex Transm Infect; 2011 Oct; 87(6):458-63. PubMed ID: 21636616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.